© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
All News
The Controversy Over Omega-3 Fatty Acids
A failed trial at the American Heart Association leads to pointed fingers at game-changing research on Vascepa, and counter claims of "manufactured controversy."
FDA Updates for Week of June 20, 2022
June 25, 2022
FDA approves tumor-agnostic cancer therapy, Clovis pulls Rubraca indication, Purdue launches opioid reversal, FDA plans advisory committee meeting for Xphozah, and Manarini and AbbVie submit applications.
HRQOL Declined in Certain Areas for Patients With AD During the Pandemic
June 24, 2022
Certain problems such as pain/discomfort, worrying and fear of the persistence/recurrence of atopic dermatitis (AD) became more common among patients with AD since the start of the COVID-19 pandemic.
Please Take Our Annual Pharmacy Survey! Five Minutes, Tops.
June 23, 2022
Respondents can win a $250 gift card.
Making Contraception More Available
June 23, 2022
Demand for birth control obtained through telehealth or without a prescription continues to grow, and some states have loosened up their rules. Meanwhile, groups and organizations involved in contraception are bracing themselves for the effects of the U.S. Supreme Court decision today overturned Roe v. Wade and the constitutional right to abortion.
FDA Updates for Week of June 13, 2022
June 18, 2022
In COVID-19 news, the FDA expanded emergency use of the Moderna COVID-19 vaccine and the Pfizer-BioNTech COVID-19 Vaccine for children down to 6 months of age. The FDA also approved Skyrizi for Crohn’s disease, Olumiant for alopecia, as well as two rare disease therapies: Imcivree for obesity associated BBS and Amvuttra for neuropathy associated with rare disease. Additionally, FDA extended the PDUFA date Brukinsa.
AI Could Dramatically Change OSA Diagnosis, But Only If Key Barriers are Cleared
June 16, 2022
Technical and regulatory hurdles abound, but another challenge is finding enough providers who are comfortable and competent with artificial intelligence technology.
Anthem Changing Name to Elevance Health
June 16, 2022
The company also announced yesterday that will revive Wellpoint name in some markets.
Enbrel Stays Above the Biosimilar Fray, but Humira Biosimilars May Nip at its Heels
June 15, 2022
Amgen’s biologic won’t have biosimilar competition till 2029. But the possibility that up to 11 Humira biosimilars may come on the market in 2023 could exert some downward pressure on Enbrel’s price.
Patients With Cancer Faced Heightened Economic, Social, Psychological Impacts From COVID-19
June 15, 2022
A review of multiple studies found the COVID-19 exacerbated the economic, social and psychological difficulties that patients with cancer were already facing because of their cancer.
The Future of Employer Sponsored Healthcare Plans Is Cost Management
June 12, 2022
Adding tax-preferred savings, perhaps with an employer match, can prompt employees to accumulate assets so they are prepared to shoulder out-of-pocket costs. Using reference-based pricing can establish benchmark fees and put a ceiling on payments across a network.